NCT02302118

Brief Summary

Comparison of the oncological outcome of patients who underwent esophagogastrectomy versus extended gastrectomy due to carcinomas of the esophagogastric junction (Siewert type II)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
128

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2013

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2013

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

November 24, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 26, 2014

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2015

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2015

Completed
Last Updated

December 3, 2015

Status Verified

December 1, 2015

Enrollment Period

2.5 years

First QC Date

November 24, 2014

Last Update Submit

December 2, 2015

Conditions

Carcinomas of the Esophagogastric Junction

Keywords

esophageal carcinomakardia carcinoma

Outcome Measures

Primary Outcomes (1)

  • Overall survival

    2 years

Study Arms (1)

Surgical approach

Group A: Esophagogastrectomy Group B: Extended gastrectomy

Procedure: Esophagogastrectomy

Interventions

EsophagogastrectomyPROCEDURE

Esophagogastrectomy

Surgical approach

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with carcinomas of the esophagogastric junction

You may qualify if:

  • Carcinoma of the esophagogastric junction (AEG type II)
  • Age of Minimum 18 years

You may not qualify if:

  • non

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Hamburg Eppendorf

Hamburg, 20246, Germany

Location

MeSH Terms

Conditions

Esophageal Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsDigestive System DiseasesEsophageal DiseasesGastrointestinal Diseases

Study Officials

  • Jakob R Izbicki, MD

    Universitätsklinikum Hamburg-Eppendorf

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 24, 2014

First Posted

November 26, 2014

Study Start

April 1, 2013

Primary Completion

October 1, 2015

Study Completion

November 1, 2015

Last Updated

December 3, 2015

Record last verified: 2015-12

Locations

DE(1)